Related Experiment Video
Updated: Sep 15, 2025
11:12
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
8.1K
Emerin expression stratification across breast cancer subtypes.
Thaysa Ghiarone1, Emily Hansen1,2, James M Holaska1,2
1Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ.
Biorxiv : the Preprint Server for Biology
|July 17, 2025
Summary
Emerin, a nuclear protein, is significantly reduced in aggressive breast cancers. Its loss correlates with advanced stage, higher proliferation, and specific molecular subtypes, indicating its potential as a biomarker.
Area of Science:
- Oncology
- Cell Biology
- Molecular Pathology
Background:
- Nuclear dysmorphism is a key indicator of tumor aggressiveness, affecting cancer invasion and metastasis.
- Emerin, a nuclear envelope protein, is crucial for nuclear integrity and has shown an inverse correlation with breast cancer aggressiveness in prior studies.
- Previous research lacked the power to definitively link emerin loss to specific cancer characteristics like stage, grade, proliferation, or molecular phenotype.
Purpose of the Study:
- To investigate the correlation between emerin expression at the nuclear envelope and various breast cancer characteristics.
- To determine if emerin loss is associated with tumor stage, grade, proliferation rates, and molecular subtypes in a cohort of 243 breast cancer patients.
Main Methods:
- Analysis of emerin expression at the nuclear envelope in 243 breast cancer patient samples.
- Correlation of emerin levels with tumor grade, stage, Ki-67 proliferation index, HER2, ER, and PR status.
- Comparison of emerin expression between different breast cancer subtypes, including invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), ductal carcinoma in situ (DCIS), and triple-negative breast cancer (TNBC).
Main Results:
- Significantly reduced emerin expression was observed in IDC, ILC, and DCIS compared to normal breast tissue.
- Emerin loss correlated with advanced tumor stage, higher Ki-67 proliferation rates, elevated HER2 levels, and decreased ER/PR expression.
- Consistently reduced emerin expression was found in triple-negative breast cancer (TNBC) and other receptor-negative subtypes.
Conclusions:
- Reduced emerin expression is associated with aggressive breast cancer phenotypes.
- Emerin loss correlates with key indicators of poor prognosis, including advanced stage and high proliferation.
- Emerin represents a potential prognostic biomarker and therapeutic target for aggressive breast cancer subtypes.
